Clinicopathological characteristics of SPTCLs according to HAVCR2 genotype
| Characteristic . | WT . | Y82C . | Unknown . | Total . | P . |
|---|---|---|---|---|---|
| Clinical features | |||||
| Age | |||||
| Median (range), y | 40 (16-74) | 26 (8-62) | 52 (35-68) | 32 (8-74) | .002* |
| <30 y | 6 (25.0%) | 18 (72.0%) | 0 (0.0%) | 24 (45.3%) | .001† |
| ≥30 y | 18 (75.0%) | 7 (28.0%) | 4 (100.0%) | 29 (54.7%) | |
| Sex | .404† | ||||
| Male | 6 (25.0%) | 9 (36.0%) | 1 (25.0%) | 16 (30.2%) | |
| Female | 18 (75.0%) | 16 (64.0%) | 3 (75.0%) | 37 (69.8%) | |
| HLH/HLH–like systemic illness | <.001† | ||||
| No | 22 (95.7%) | 11 (45.8%) | 2 (100.0%) | 35 (71.4%) | |
| Yes | 1 (4.3%) | 13 (54.2%) | 0 (0.0%) | 14 (28.6%) | |
| BM involvement | 1.000‡ | ||||
| Absent | 21 (100.0%) | 12 (95.7%) | 0 (0.0%) | 43 (93.5%) | |
| Present | 0 (0.0%) | 1 (4.3%) | 2 (100.0%) | 3 (6.5%) | |
| First-line treatments | .069‡ | ||||
| Chemotherapy | 16 (88.9%) | 14 (63.6%) | 3 (100.0%) | 33 (76.7%) | |
| Immunosuppressive | 2 (11.1%) | 8 (36.4%) | 0 (0.0%) | 10 (23.3%) | |
| HSCT§ | .070‡ | ||||
| No | 8 (80.0%) | 3 (33.3%) | 2 (100.0%) | 13 (61.9%) | |
| Yes | 2 (20.0%) | 6 (66.7%) | 0 (0.0%) | 8 (38.1%) | |
| Relapse | .345† | ||||
| No | 17 (73.9%) | 14 (60.9%) | 3 (100.0%) | 34 (69.4%) | |
| Yes | 6 (26.1%) | 9 (39.1%) | 0 (0.0%) | 15 (30.6%) | |
| 5-y RFS | .001* | ||||
| Median (range), m | 57 (1-60) | 11 (1-60) | 60 (16-60) | 30 (1-60) | |
| Death | 1.000‡ | ||||
| No | 21 (87.5%) | 21 (87.5%) | 3 (100.0%) | 45 (88.2%) | |
| Yes | 3 (12.5%) | 3 (12.5%) | 0 (0.0%) | 6 (11.8%) | |
| 5-y OS | .004* | ||||
| Median (range), m | 60 (2-60) | 25 (1-60) | 60 (16-60) | 39 (1-60) | |
| 5-y DSS | .003* | ||||
| Median (range), m | 59.5 (2-60) | 19 (1-60) | 60 (16-60) | 37 (1-60) | |
| Histopathological features | |||||
| Necrosis | .314† | ||||
| Absent | 14 (66.7%) | 13 (52.0%) | 1 (50.0%) | 28 (58.3%) | |
| Present | 7 (33.3%) | 12 (48.0%) | 1 (50.0%) | 20 (41.7%) | |
| Granulomatous inflammation | .037‡ | ||||
| Absent | 17 (81.0%) | 25 (100.0%) | 2 (100.0%) | 44 (91.7%) | |
| Present | 4 (19.0%) | 0 (0.0%) | 0 (0.0%) | 4 (8.3%) | |
| Lipogranuloma | .293‡ | ||||
| Absent | 16 (76.2%) | 22 (88.0%) | 2 (100.0%) | 40 (83.3%) | |
| Present | 5 (23.8%) | 3 (12.0%) | 0 (0.0%) | 8 (16.7%) | |
| pSTAT3 IHC∥ | .015† | ||||
| Low | 12 (70.6%) | 4 (25.0%) | 0 (0.0%) | 16 (48.5%) | |
| High | 5 (29.4%) | 12 (75.0%) | 0 (0.0%) | 17 (51.5%) | |
| CCR4 IHC‖ | .019† | ||||
| Low | 5 (27.8%) | 12 (66.7%) | 0 (0.0%) | 17 (47.2%) | |
| High | 13 (72.2%) | 6 (33.3%) | 0 (0.0%) | 19 (52.8%) | |
| Total | 24 (45.3%) | 25 (47.2%) | 4 (7.5%) | 53 (100.0%) | |
| Characteristic . | WT . | Y82C . | Unknown . | Total . | P . |
|---|---|---|---|---|---|
| Clinical features | |||||
| Age | |||||
| Median (range), y | 40 (16-74) | 26 (8-62) | 52 (35-68) | 32 (8-74) | .002* |
| <30 y | 6 (25.0%) | 18 (72.0%) | 0 (0.0%) | 24 (45.3%) | .001† |
| ≥30 y | 18 (75.0%) | 7 (28.0%) | 4 (100.0%) | 29 (54.7%) | |
| Sex | .404† | ||||
| Male | 6 (25.0%) | 9 (36.0%) | 1 (25.0%) | 16 (30.2%) | |
| Female | 18 (75.0%) | 16 (64.0%) | 3 (75.0%) | 37 (69.8%) | |
| HLH/HLH–like systemic illness | <.001† | ||||
| No | 22 (95.7%) | 11 (45.8%) | 2 (100.0%) | 35 (71.4%) | |
| Yes | 1 (4.3%) | 13 (54.2%) | 0 (0.0%) | 14 (28.6%) | |
| BM involvement | 1.000‡ | ||||
| Absent | 21 (100.0%) | 12 (95.7%) | 0 (0.0%) | 43 (93.5%) | |
| Present | 0 (0.0%) | 1 (4.3%) | 2 (100.0%) | 3 (6.5%) | |
| First-line treatments | .069‡ | ||||
| Chemotherapy | 16 (88.9%) | 14 (63.6%) | 3 (100.0%) | 33 (76.7%) | |
| Immunosuppressive | 2 (11.1%) | 8 (36.4%) | 0 (0.0%) | 10 (23.3%) | |
| HSCT§ | .070‡ | ||||
| No | 8 (80.0%) | 3 (33.3%) | 2 (100.0%) | 13 (61.9%) | |
| Yes | 2 (20.0%) | 6 (66.7%) | 0 (0.0%) | 8 (38.1%) | |
| Relapse | .345† | ||||
| No | 17 (73.9%) | 14 (60.9%) | 3 (100.0%) | 34 (69.4%) | |
| Yes | 6 (26.1%) | 9 (39.1%) | 0 (0.0%) | 15 (30.6%) | |
| 5-y RFS | .001* | ||||
| Median (range), m | 57 (1-60) | 11 (1-60) | 60 (16-60) | 30 (1-60) | |
| Death | 1.000‡ | ||||
| No | 21 (87.5%) | 21 (87.5%) | 3 (100.0%) | 45 (88.2%) | |
| Yes | 3 (12.5%) | 3 (12.5%) | 0 (0.0%) | 6 (11.8%) | |
| 5-y OS | .004* | ||||
| Median (range), m | 60 (2-60) | 25 (1-60) | 60 (16-60) | 39 (1-60) | |
| 5-y DSS | .003* | ||||
| Median (range), m | 59.5 (2-60) | 19 (1-60) | 60 (16-60) | 37 (1-60) | |
| Histopathological features | |||||
| Necrosis | .314† | ||||
| Absent | 14 (66.7%) | 13 (52.0%) | 1 (50.0%) | 28 (58.3%) | |
| Present | 7 (33.3%) | 12 (48.0%) | 1 (50.0%) | 20 (41.7%) | |
| Granulomatous inflammation | .037‡ | ||||
| Absent | 17 (81.0%) | 25 (100.0%) | 2 (100.0%) | 44 (91.7%) | |
| Present | 4 (19.0%) | 0 (0.0%) | 0 (0.0%) | 4 (8.3%) | |
| Lipogranuloma | .293‡ | ||||
| Absent | 16 (76.2%) | 22 (88.0%) | 2 (100.0%) | 40 (83.3%) | |
| Present | 5 (23.8%) | 3 (12.0%) | 0 (0.0%) | 8 (16.7%) | |
| pSTAT3 IHC∥ | .015† | ||||
| Low | 12 (70.6%) | 4 (25.0%) | 0 (0.0%) | 16 (48.5%) | |
| High | 5 (29.4%) | 12 (75.0%) | 0 (0.0%) | 17 (51.5%) | |
| CCR4 IHC‖ | .019† | ||||
| Low | 5 (27.8%) | 12 (66.7%) | 0 (0.0%) | 17 (47.2%) | |
| High | 13 (72.2%) | 6 (33.3%) | 0 (0.0%) | 19 (52.8%) | |
| Total | 24 (45.3%) | 25 (47.2%) | 4 (7.5%) | 53 (100.0%) | |
BM, bone marrow; DSS, disease-specific survival; HLH, hemophagocytic lymphohistiocytosis; HSCT, hematopoietic stem cell transplantation; OS, overall survival; RFS, relapse-free survival.
Compared between HAVCR2WT and HAVCR2Y82C by using the Mann-Whitney U test.
Compared between HAVCR2WT and HAVCR2Y82C by using the χ2 test.
Compared between HAVCR2WT and HAVCR2Y82C by using Fisher’s exact test.
Either autologous or allogeneic transplantation.
Used median values as cutoffs.